Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma
A retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment
Osteosarcoma Recurrent|Osteosarcoma Metastatic
OTHER: observation
Response to Gemcitabina - Docetaxel Treatment, assessed as overall survival (12 months), 12 months
A retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment